Table 1.
Patient characteristics and the relationship between routine clinicopathological variables and incidence of immune-related adverse events in patients with NSCLC treated with first-line pembrolizumab (* non-squamous only, where available (n = 202)).
| Characteristics | Total | Without irAE | With irAE | p | |
|---|---|---|---|---|---|
| n = 262 | n = 179 | n = 83 | |||
| n (%) | n (%) | n (%) | |||
| Age (years) | <75 | 220 (84) | 155 (87) | 65 (78) | 0.089 |
| ≥75 | 42 (16) | 24 (13) | 18 (22) | ||
| Sex | Male | 114 (44) | 81 (45) | 33 (40) | 0.404 |
| Female | 148 (56) | 98 (55) | 50 (60) | ||
| ECOG-performance status | 0/1 | 218 (83) | 146 (82) | 72 (87) | 0.296 |
| 2 | 44 (17) | 33 (18) | 11 (13) | ||
| Histologic subtype | Squamous | 54 (21) | 32 (18) | 22 (17) | 0.108 |
| Non-squamous | 208 (79) | 147 (82) | 61 (73) | ||
| PD-L1 expression | <90 | 127 (48) | 94 (53) | 33 (40) | 0.055 |
| ≥90 | 135 (52) | 85 (47) | 50(60) | ||
| KRAS status * | Wildtype | 95 (47) | 65 (45) | 30 (51) | 0.485 |
| Mutant | 107 (53) | 78 (55) | 29 (49) | ||